Back to Search Start Over

Presentation of BK polyomavirus-associated hemorrhagic cystitis after allogeneic hematopoietic cell transplantation.

Authors :
Imlay H
Xie H
Leisenring WM
Duke ER
Kimball LE
Huang ML
Pergam SA
Hill JA
Jerome KR
Milano F
Nichols WG
Pang PS
Hirsch HH
Limaye AP
Boeckh M
Source :
Blood advances [Blood Adv] 2020 Feb 25; Vol. 4 (4), pp. 617-628.
Publication Year :
2020

Abstract

BK polyomavirus (BKPyV) has been associated with hemorrhagic cystitis (HC) after allogeneic hematopoietic cell transplantation (HCT), but the natural history of HC and factors associated with the clinical course are incompletely understood. We retrospectively analyzed allogeneic HCT patients transplanted from 2007-2017 who presented after platelet engraftment or after day 28 post-HCT with BKPyV-associated HC (BKPyV-HC), which was defined as a positive urine BKPyV PCR, ≥1 plasma BKPyV viral load result, and macroscopic hematuria (Bedi grade ≥2). Factors associated with resolution of macroscopic hematuria and resolution of all cystitis symptoms within 90 days after HC diagnosis were investigated in multivariable models. In 128 patients with BKPyV-HC, the median times from diagnosis to resolution of all symptoms, macroscopic hematuria, and urinary clots (present in 55% [71/128]) were 24 days (15-44), 17 days (10-30), and 14 days (5-26), respectively. Ninety percent of patients had BKPyV viremia at the onset of HC with a median viral load of 1850 copies/mL (interquartile range, 240-8550). In multivariable models, high plasma viral load (≥10 000 copies/mL) and cytopenias at the beginning of BKPyV-HC were significantly associated with longer macroscopic hematuria and cystitis symptoms. Use of cidofovir was not associated with shorter duration of illness. In conclusion, BKPyV-HC after allogeneic HCT is characterized by prolonged and severe symptoms and requires improved management strategies. High-grade viremia and cytopenias were associated with a longer duration of BKPyV-associated HC. Accurate descriptions of disease and factors associated with prolonged recovery will inform end points of future clinical trials.<br /> (© 2020 by The American Society of Hematology.)

Details

Language :
English
ISSN :
2473-9537
Volume :
4
Issue :
4
Database :
MEDLINE
Journal :
Blood advances
Publication Type :
Academic Journal
Accession number :
32074279
Full Text :
https://doi.org/10.1182/bloodadvances.2019000802